This review assessed adjuvant chemotherapy following curative liver resection for hepatocellular carcinoma. The authors concluded that although post-operative transarterial chemotherapy may improve survival, the limitations of the included studies prevented a firm conclusion. The tentative conclusions are appropriate.
according to intention-to-treat. When necessary, actuarial survival curves were used to estimate the number of deaths or recurrences. Mean differences (MDs) between the treatment and control groups were estimated, along with 95% confidence intervals (CIs).
Methods of synthesis
How were the studies combined? The studies were combined where two or more studies of a therapeutic modality were available (7 studies were excluded because only one study evaluated a particular treatment modality). The methods of Peto, and DerSimonian and Laird were used; only the results for the latter were reported. The studies were weighted, based on the inverse of the variance.
How were differences between studies investigated?
The chi-squared test was used to investigate statistical heterogeneity. RCTs where the comparison was with no adjuvant treatment were analysed separately (core analyses). A pre-specified sensitivity analysis was conducted on the basis of study design and control group treatment.
Results of the review
Twenty-one studies were included: 10 RCTs (n=634) and 11 non-RCTs (n=944).
Pre-operative transarterial chemotherapy (2 RCTs; 7 non-RCTs).
Core analysis (2 RCTs): there was no significant difference in survival between pre-operative transarterial chemotherapy and no adjuvant treatment at 1 year (MD 0.5%, 95% CI: -11, 11.8), 2 years (MD -6%, 95% CI: -32.4, 20.1) or 3 years (MD -0.2%, 95% CI: -14.1, 13.7). There was also no significant difference in the cumulative probability of no recurrence at 1, 2 or 3 years (data reported in the paper). There was statistically significant heterogeneity between the control groups for survival at 3 years only (P=0.003). When non-RCTs comparing treatment with no adjuvant treatment were added to the analysis the effect of pre-operative transarterial chemotherapy on survival remained non significant at each follow-up period, although there was a statistically significant beneficial effect on the cumulative probability of no recurrence at 2 years, but not 1 or 3 years. This remained significant when studies in which the control group received treatment in some cases were included. There was statistically significant heterogeneity for some of these analyses.
Post-operative transarterial chemotherapy (4 RCTs; 3 non-RCTs).
Core analysis (4 RCTs): there was a statistically significant benefit in survival for post-operative transarterial chemotherapy compared with no adjuvant treatment at 2 years (MD 22.8%, 95% CI: 8.6, 36.9, P=0.002) and 3 years (MD 27.6%, 95% CI: 8.2, 47.1, P=0.005), but not 1 year (MD 13.2%, 95% CI: -1.8, 28.2, P=0.08). There was a significant improvement in the cumulative probability of no recurrence at 1 year (MD 28.8%, 95% CI: 16.7, 40.8, P<0.001), 2 years (MD 27.6%, 95% CI: 8.2, 47.1, P=0.005) and 3 years (MD 28%, 95% CI: 8.2, 47.9, P=0.006). There was significant heterogeneity for cumulative probability of no recurrence at 3 years only (P=0.03). When non-RCTs were added to the analysis there was also a beneficial effect of treatment compared with no treatment for survival at 1 year. The inclusion of non-RCTs increased heterogeneity.
Systemic chemotherapy (1 RCT; 1 non-RCT).
There was no significant difference in survival between systemic chemotherapy (5-fluorouracil) and no adjuvant treatment at 1 year (MD 3%, 95% CI: -7.2, 13), 2 years (MD 1.2%, 95% CI: -9.6, 12) or 3 years (MD 2.5%, 95% CI: -8.6, 13.6). There was also no significant difference in the cumulative probability of no recurrence at 1 or 3 years (data reported in the paper). There was statistically significant heterogeneity for survival at 1, 2 and 3 years and in the probability of no recurrence at 1 year.
Post-operative systemic chemotherapy combined with transarterial chemotherapy (3 RCTs).
Core analysis (2 RCTs): there was no significant difference in survival between the combination treatment and no
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Copyright © 2017 University of York adjuvant treatment at 1 year (MD -9.2%, 95% CI: -23.2, 5) or 3 years (MD -3.4%, 95% CI: -19.3, 12.4). Treatment had a detrimental effect on the cumulative probability of no recurrence at 1 year (MD -19.7%, 95% CI: -35.2, -4.3, P=0.01) and 3 years (MD -21.3%, 95% CI: -41.6, -1, P=0.04). There was no statistically significant heterogeneity. When a study with an active control group was added to the analysis there was still no beneficial effect of treatment on either outcome.
Authors' conclusions
After curative resection, post-operative transarterial chemotherapy may improve survival and the cumulative probability of no recurrence. However, a firm conclusion regarding this therapy was hampered by the limitations of the included studies. Although data were not provided, the authors stated that most of the studies were performed in Asian patients and the data could not be extrapolated to non-Asian populations.
CRD commentary
The review question was clear in terms of the intervention, outcome, participants and study design. Some relevant electronic databases were searched, although details of the search strategy were not provided. No attempt to identify unpublished data appears to have been made and only full reports were eligible for inclusion; studies may therefore have been missed. The study selection and quality assessment were carried out in duplicate, but since there was no information on the data extraction process used there is a possibility of some error or bias. Although some appropriate details on the individual studies were provided, it would have been helpful to have had more information on the study participants.
It was appropriate to group the RCTs separately and on the basis of whether or not the control group received no adjuvant treatment. There was evidence of statistical heterogeneity in some of the analyses, therefore some of the pooling may have been inappropriate. The authors reported that they carried out a quality assessment, but did not report the findings. They did, however, discuss some general limitations of the included studies. On the basis of such limitations, it was appropriate that they made tentative conclusions and drew attention to the issue of generalisability to other racial groups.
